"目錄號: HY-13638

Apoptosis-

GDC-0152 是一種有效的IAPs抑制劑滋恬，能夠分別與XIAPBIR3 結(jié)合域减俏，ML-IAP的 BIR 結(jié)合域将饺，cIAP1和cIAP2的 BIR3 結(jié)合域結(jié)合矢渊，Ki值分別為 28，14躬审，17 和 43 nM棘街。

IAP

相關(guān)產(chǎn)品

LCL161-Birinapant-BV6-CUDC-427-AZD5582-Embelin-SM-164-AT-406-MX69-UC-112-

生物活性

Description

GDC-0152 is a potent inhibitor ofIAPswhich binds to theXIAPBIR3 domain, the BIR domain ofML-IAP, and the BIR3 domains ofcIAP1andcIAP2withKivalues of 28, 14, 17, and 43 nM, respectively.

IC50& Target

Ki: 28 nM (XIAP BIR3), 14 nM (MLIAP-BIR3), 17 nM (cIAP1-BIR3), 43 nM (cIAP2-BIR3)

In Vitro

GDC-0152 can block protein?protein interactions that involve IAP proteins and pro-apoptotic molecules. Using transiently transfected HEK293T cells, GDC-0152 is shown to disrupt XIAP binding to partially processed caspase-9 and to disrupt the association of ML-IAP, cIAP1, and cIAP2 with Smac. In melanoma SK-MEL28 cells, the endogenous association of ML-IAP and Smac is also effectively abolished by GDC-0152. GDC-0152 leads to a decrease in cell viability in the MDA-MB-231 breast cancer cell line, while having no effect on normal human mammary epithelial cells (HMEC). GDC-0152 is found to activate caspases 3 and 7 in a dose- and time-dependent manner. GDC-0152 is shown to induce rapid degradation of cIAP1 in A2058 melanoma cells. It effectively induces degradation of cIAP1 at concentrations as low as 10 nM, consistent with its affinity for cIAP1[1].

In Vivo

GDC-0152 has moderate predicted hepatic clearance based on metabolic stability assays conducted using human liver microsomes. Plasma?protein binding of GDC-0152 is moderate and comparable among mice (88?91%), rats (89?91%), dogs (81?90%), monkeys (76?85%), and humans (75?83%) over the range of concentrations investigated (0.1?100 μM); higher plasma?protein binding is observed in rabbits (95?96%). GDC-0152 does not preferentially distribute to red blood cells with blood?plasma partition ratios ranging from 0.6 to 1.1 in all species tested. The pharmacokinetics for GDC-0152 is achieved with a C max of 53.7 μM and AUC of 203.5 h·μM[1].

Clinical Trial

NCT00977067

Genentech, Inc.

Solid Cancers

June 2007

Phase 1

View MoreCollapse

References

[1].Flygare JA, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.